Cover Image
Market Research Report

Psoriatic Arthritis Treatment Market by Drug Type (NSAIDs, DMARDs, Biologics, and Others), Type (Prescription, and OTC), and Route of Administration (Topical, Oral, and Injectable): Global Opportunity Analysis and Industry Forecast, 2019-2026

Published by Allied Market Research Product code 927311
Published Content info 228 Pages
Delivery time: 2-3 business days
Price
Back to Top
Psoriatic Arthritis Treatment Market by Drug Type (NSAIDs, DMARDs, Biologics, and Others), Type (Prescription, and OTC), and Route of Administration (Topical, Oral, and Injectable): Global Opportunity Analysis and Industry Forecast, 2019-2026
Published: January 1, 2020 Content info: 228 Pages
Description

The psoriatic arthritis treatment market was valued at $7,860 million in 2018, and is estimated to reach at $13,744 million by 2026, registering a CAGR of 7.2% from 2019 to 2026.

Psoriatic arthritis is an autoimmune disease caused by an attack of body's immune system on skin and joint. The disease is characterized by stiffness, swelling in the joints, and pain. Symmetric psoriatic arthritis, asymmetric psoriatic arthritis, spondylitis, distal psoriatic arthritis, and arthritis mutilans are the different types of psoriatic arthritis. Symptoms associated with this disorder include low back pain, conjunctivitis, swollen joint, nail pitting, and foot pain. The disorder is more prevalent among patients already suffering from psoriasis. Psoriatic arthritis can be diagnosed with tests such as rheumatoid factor (RF), joint fluid test, X-ray, and magnetic resonance imaging (MRI). Drugs used to treat psoriatic arthritis disease include NSAIDs, disease-modifying antirheumatic drugs (DMARDs), biologics, immunosuppressant drugs, and others.

Significant increase in prevalence of psoriatic arthritis, rise in demand for psoriatic arthritis pharmacotherapy, strong pipeline of biosimilar & biologic products, stressful lifestyle resulting in the overstimulation of immune system, and rise in geriatric population are the key factors that fuel the growth of the global psoriatic arthritis treatment market. Moreover, rise in adoption of psoriatic arthritis treatment medications, increase in R&D activities to develop new products for effective treatment of psoriatic arthritis, frequent product launches by key players, surge in awareness toward availability of treatment for psoriatic arthritis, and increase in risk of diseases are other factors that contribute toward the growth of the market. However, lack of standardization tools for diagnosis and high cost of treatment are expected to hamper the market growth.

The global psoriatic arthritis treatment market is segmented into drug type, type, route of administration, and region. By drug type, the market is categorized into NSAIDs, DMARDs, biologics, and others. On the basis of type, the market is divided into prescription, and OTC. According to route of administration, it is segregated into topical, oral, and injectable. Region wise, the market is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa and rest of LAMEA).

KEY BENEFITS FOR STAKEHOLDERS

  • The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
  • It offers a quantitative analysis from 2018 to 2026, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities.
  • A comprehensive analysis of all the geographical regions is provided to determine the existing opportunities.
  • The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global market.

KEY MARKET SEGMENTS

By Drug Type

  • NSAIDs
  • DMARDs
  • Biologics
  • Others

By Type

  • Prescription
  • OTC

By Route of Administration

  • Topical
  • Oral
  • Injectable

By Region

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • Australia
  • India
  • South Korea
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA
  • LIST OF KEY PLAYERS PROFILED IN THE REPORT
  • AbbVie Inc.
  • Amgen Inc.
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Eli Lilly And Company
  • Johnson & Johnson
  • Merck & Co Inc.
  • Novartis AG
  • Pfizer Inc.
  • UCB S.A.
  • LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request.)
  • F. Hoffmann-La Roche AG
  • Valeant Pharmaceuticals International, Inc.
  • Abbott Laboratories
Table of Contents
Product Code: LI_206316

Table of Contents

Chapter 1: Introduction

  • 1.1. Report Description
  • 1.2. Key Benefits For Stakeholders
  • 1.3. Key Market Segments
    • 1.3.1. List of Key Players Profiled In The Report
  • 1.4. Research Methodology
    • 1.4.1. Secondary Research
    • 1.4.2. Primary Research
    • 1.4.3. Analyst Tools And Models

Chapter 2: Executive Summary

  • 2.1. Key Findings of The Study
  • 2.2. Cxo Perspective

Chapter 3: Market Overview

  • 3.1. Market Definition And Scope
  • 3.2. Key Findings
    • 3.2.1. Top Investment Pockets
  • 3.3. Porter'S Five Force Analysis
  • 3.4. Market Dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Rise In Prevalence of Psoriasis & Psoriatic Arthritis Disease
      • 3.4.1.2. Increase In Number of Pipeline Drugs
      • 3.4.1.3. Increase In Government Expenditure On Healthcare
    • 3.4.2. Restraint
      • 3.4.2.1. Poor Demand In Under Developed Countries
    • 3.4.3. Opportunities
      • 3.4.3.1. Growth Opportunities In Emerging Markets
    • 3.4.4. Impact Analysis

Chapter 4: Psoriatic Arthritis Treatment Market, By Drug Type

  • 4.1. Overview
    • 4.1.1. Market Size And Forecast
  • 4.2. Nsaids
    • 4.2.1. Key Market Trends, Growth Factors, And Opportunities
    • 4.2.2. Market Size And Forecast, By Region
    • 4.2.3. Market Analysis, By Country
  • 4.3. Dmards
    • 4.3.1. Key Market Trends, Growth Factors, And Opportunities
    • 4.3.2. Market Size And Forecast
    • 4.3.3. Market Analysis, By Country
  • 4.4. Biologics
    • 4.4.1. Key Market Trends, Growth Factors, And Opportunities
    • 4.4.2. Market Size And Forecast
    • 4.4.3. Market Analysis, By Country
  • 4.5. Others
    • 4.5.1. Key Market Trends, Growth Factors, And Opportunities
    • 4.5.2. Market Size And Forecast
    • 4.5.3. Market Analysis, By Country

Chapter 5: Psoriatic Arthritis Treatment Market, By Type

  • 5.1. Overview
    • 5.1.1. Market Size And Forecast
  • 5.2. Prescription
    • 5.2.1. Market Size And Forecast, By Region
    • 5.2.2. Market Analysis, By Country
  • 5.3. Otc
    • 5.3.1. Market Size And Forecast, By Region
    • 5.3.2. Market Analysis, By Country

Chapter 6: Psoriatic Arthritis Treatment Market, By Route of Administration

  • 6.1. Overview
    • 6.1.1. Market Size And Forecast
  • 6.2. Injectable
    • 6.2.1. Market Size And Forecast, By Region
    • 6.2.2. Market Analysis, By Country
  • 6.3. Oral
    • 6.3.1. Market Size And Forecast, By Region
    • 6.3.2. Market Analysis, By Country
  • 6.4. Topical
    • 6.4.1. Market Size And Forecast, By Region
    • 6.4.2. Market Analysis, By Country

Chapter 7: Psoriatic Arthritis Treatment Market, By Region

  • 7.1. Overview
    • 7.1.1. Market Size And Forecast
  • 7.2. North America
    • 7.2.1. Key Market Trends, Growth Factors, And Opportunities
    • 7.2.2. Market Size And Forecast, By Country
      • 7.2.2.1. U.S.
      • 7.2.2.1.1. U.S. Psoriatic Arthritis Treatment Market, By Drug Type
      • 7.2.2.1.2. U.S. Psoriatic Arthritis Treatment Market, By Type
      • 7.2.2.1.3. U.S. Psoriatic Arthritis Treatment Market, By Route of Administration
      • 7.2.2.2. Canada
      • 7.2.2.2.1. Canada Psoriatic Arthritis Treatment Market, By Drug Type
      • 7.2.2.2.2. Canada Psoriatic Arthritis Treatment Market, By Type
      • 7.2.2.2.3. Canada Psoriatic Arthritis Treatment Market, By Route of Administration
      • 7.2.2.3. Mexico
      • 7.2.2.3.1. Mexico Psoriatic Arthritis Treatment Market, By Drug Type
      • 7.2.2.3.2. Mexico Psoriatic Arthritis Treatment Market, By Type
      • 7.2.2.3.3. Mexico Psoriatic Arthritis Treatment Market, By Route of Administration
    • 7.2.3. North America Market Size And Forecast, By Drug Type
    • 7.2.4. North America Market Size And Forecast, By Type
    • 7.2.5. North America Market Size And Forecast, By Route of Administration
  • 7.3. Europe
    • 7.3.1. Key Market Trends, Growth Factors, And Opportunities
    • 7.3.2. Market Size And Forecast, By Country
      • 7.3.2.1. Germany
      • 7.3.2.1.1. Germany Psoriatic Arthritis Treatment Market, By Drug Type
      • 7.3.2.1.2. Germany Psoriatic Arthritis Treatment Market, By Type
      • 7.3.2.1.3. Germany Psoriatic Arthritis Treatment Market, By Route of Administration7.3.2.2. France
      • 7.3.2.2.1. France Psoriatic Arthritis Treatment Market, By Drug Type
      • 7.3.2.2.2. France Psoriatic Arthritis Treatment Market, By Type
      • 7.3.2.2.3. France Psoriatic Arthritis Treatment Market, By Route of Administration
      • 7.3.2.3. Uk
      • 7.3.2.3.1. Uk Psoriatic Arthritis Treatment Market, By Drug Type
      • 7.3.2.3.2. Uk Psoriatic Arthritis Treatment Market, By Type
      • 7.3.2.3.3. Uk Psoriatic Arthritis Treatment Market, By Route of Administration
      • 7.3.2.4. Italy
      • 7.3.2.4.1. Italy Psoriatic Arthritis Treatment Market, By Drug Type
      • 7.3.2.4.2. Italy Psoriatic Arthritis Treatment Market, By Type
      • 7.3.2.4.3. Italy Psoriatic Arthritis Treatment Market, By Route of Administration
      • 7.3.2.5. Spain
      • 7.3.2.5.1. Spain Psoriatic Arthritis Treatment Market, By Drug Type
      • 7.3.2.5.2. Spain Psoriatic Arthritis Treatment Market, By Type
      • 7.3.2.5.3. Spain Psoriatic Arthritis Treatment Market, By Route of Administration
      • 7.3.2.6. Rest of Europe
      • 7.3.2.6.1. Rest of Europe Psoriatic Arthritis Treatment Market, By Drug Type
      • 7.3.2.6.2. Rest of Europe Psoriatic Arthritis Treatment Market, By Type
      • 7.3.2.6.3. Rest of Europe Psoriatic Arthritis Treatment Market, By Route of Administration
    • 7.3.3. Europe Market Size And Forecast, By Drug Type
    • 7.3.4. Europe Market Size And Forecast, By Type
    • 7.3.5. Europe Market Size And Forecast, By Route of Administration
  • 7.4. Asia-Pacific
    • 7.4.1. Key Market Trends, Growth Factors, And Opportunities
    • 7.4.2. Market Size And Forecast, By Country
      • 7.4.2.1. Japan
      • 7.4.2.1.1. Japan Psoriatic Arthritis Treatment Market, By Drug Type
      • 7.4.2.1.2. Japan Psoriatic Arthritis Treatment Market, By Type
      • 7.4.2.1.3. Japan Psoriatic Arthritis Treatment Market, By Route of Administration
      • 7.4.2.2. China
      • 7.4.2.2.1. China Psoriatic Arthritis Treatment Market, By Drug Type
      • 7.4.2.2.2. China Psoriatic Arthritis Treatment Market, By Type
      • 7.4.2.2.3. China Psoriatic Arthritis Treatment Market, By Route of Administration
      • 7.4.2.3. Australia
      • 7.4.2.3.1. Australia Psoriatic Arthritis Treatment Market, By Drug Type
      • 7.4.2.3.2. Australia Psoriatic Arthritis Treatment Market, By Type
      • 7.4.2.3.3. Australia Psoriatic Arthritis Treatment Market, By Route of Administration
      • 7.4.2.4. India
      • 7.4.2.4.1. India Psoriatic Arthritis Treatment Market, By Drug Type
      • 7.4.2.4.2. India Psoriatic Arthritis Treatment Market, By Type
      • 7.4.2.4.3. India Psoriatic Arthritis Treatment Market, By Route of Administration
      • 7.4.2.5. South Korea
      • 7.4.2.5.1. South Korea Psoriatic Arthritis Treatment Market, By Drug Type
      • 7.4.2.5.2. South Korea Psoriatic Arthritis Treatment Market, By Type
      • 7.4.2.5.3. South Korea Psoriatic Arthritis Treatment Market, By Route of Administration
      • 7.4.2.6. Rest of Asia-Pacific
      • 7.4.2.6.1. Rest of Asia-Pacific Psoriatic Arthritis Treatment Market, By Drug Type
      • 7.4.2.6.2. Rest of Asia-Pacific Psoriatic Arthritis Treatment Market, By Type
      • 7.4.2.6.3. Rest of Asia-Pacific Psoriatic Arthritis Treatment Market, By Route of Administration
    • 7.4.3. Asia-Pacific Market Size And Forecast, By Drug Type
    • 7.4.4. Asia-Pacific Market Size And Forecast, By Type
    • 7.4.5. Asia-Pacific Market Size And Forecast, By Route of Administration
  • 7.5. Lamea
    • 7.5.1. Key Market Trends, Growth Factors, And Opportunities
    • 7.5.2. Market Size And Forecast, By Country
      • 7.5.2.1. Brazil
      • 7.5.2.1.1. Brazil Psoriatic Arthritis Treatment Market, By Drug Type
      • 7.5.2.1.2. Brazil Psoriatic Arthritis Treatment Market, By Type
      • 7.5.2.1.3. Brazil Psoriatic Arthritis Treatment Market, By Route of Administration
      • 7.5.2.2. Saudi Arabia
      • 7.5.2.2.1. Saudi Arabia Psoriatic Arthritis Treatment Market, By Drug Type
      • 7.5.2.2.2. Saudi Arabia Psoriatic Arthritis Treatment Market, By Type
      • 7.5.2.2.3. Saudi Arabia Psoriatic Arthritis Treatment Market, By Route of Administration
      • 7.5.2.3. South Africa
      • 7.5.2.3.1. South Africa Psoriatic Arthritis Treatment Market, By Drug Type
      • 7.5.2.3.2. South Africa Psoriatic Arthritis Treatment Market, By Type
      • 7.5.2.3.3. South Africa Psoriatic Arthritis Treatment Market, By Route of Administration
      • 7.5.2.4. Rest of Lamea
      • 7.5.2.4.1. Rest of Lamea Psoriatic Arthritis Treatment Market, By Drug Type
      • 7.5.2.4.2. Rest of Lamea Psoriatic Arthritis Treatment Market, By Type
      • 7.5.2.4.3. Rest of Lamea Psoriatic Arthritis Treatment Market, By Route of Administration
    • 7.5.3. Lamea Market Size And Forecast, By Drug Type
    • 7.5.4. Lamea Market Size And Forecast, By Type
    • 7.5.5. Lamea Market Size And Forecast, By Route of Administration

Chapter 8: Company Profiles

  • 8.1. Abbvie Inc.
    • 8.1.1. Company Overview
    • 8.1.2. Company Snapshot
    • 8.1.3. Operating Business Segments
    • 8.1.4. Product Portfolio
    • 8.1.5. Business Performance
    • 8.1.6. Key Strategic Moves And Developments
  • 8.2. Amgen Inc.
    • 8.2.1. Company Overview
    • 8.2.2. Company Snapshot
    • 8.2.3. Operating Business Segments
    • 8.2.4. Product Portfolio
    • 8.2.5. Business Performance
    • 8.2.6. Key Strategic Moves And Developments
  • 8.3. Bristol-Myers Squibb Company
    • 8.3.1. Company Overview
    • 8.3.2. Company Snapshot
    • 8.3.3. Operating Business Segments
    • 8.3.4. Product Portfolio
    • 8.3.5. Business Performance
    • 8.3.6. Key Strategic Moves And Developments
  • 8.4. Eli Lilly And Company.
    • 8.4.1. Company Overview
    • 8.4.2. Company Snapshot
    • 8.4.3. Operating Business Segments
    • 8.4.4. Product Portfolio
    • 8.4.5. Business Performance
    • 8.4.6. Key Strategic Moves And Developments
  • 8.5. Johnson & Johnson.
    • 8.5.1. Company Overview
    • 8.5.2. Company Snapshot
    • 8.5.3. Operating Business Segments
    • 8.5.4. Product Portfolio
    • 8.5.5. Business Performance
    • 8.5.6. Key Strategic Moves And Developments
  • 8.6. Merck & Co Inc.
    • 8.6.1. Company Overview
    • 8.6.2. Company Snapshot
    • 8.6.3. Operating Business Segments
    • 8.6.4. Product Portfolio
    • 8.6.5. Business Performance
  • 8.7. Mylan N.V
    • 8.7.1. Company Overview
    • 8.7.2. Company Snapshot
    • 8.7.3. Operating Business Segments
    • 8.7.4. Product Portfolio
    • 8.7.5. Business Performance
  • 8.8. Novartis Ag
    • 8.8.1. Company Overview
    • 8.8.2. Company Snapshot
    • 8.8.3. Operating Business Segments
    • 8.8.4. Product Portfolio
    • 8.8.5. Business Performance
  • 8.9. Pfizer Inc.
    • 8.9.1. Company Overview
    • 8.9.2. Company Snapshot
    • 8.9.3. Operating Business Segments
    • 8.9.4. Product Portfolio
    • 8.9.5. Business Performance
  • 8.10. Ucb S.A.
    • 8.10.1. Company Overview
    • 8.10.2. Company Snapshot
    • 8.10.3. Operating Business Segments
    • 8.10.4. Product Portfolio
    • 8.10.5. Business Performance

List of Tables

  • Table 01. Global Psoriatic Arthritis Treatment Market, By Drug Type, 2018-2026 ($Million)
  • Table 02. Nsaids Psoriatic Arthritis Treatment Market, By Region, 2018-2026 ($Million)
  • Table 03. Dmards Psoriatic Arthritis Treatment Market, By Region, 2018-2026 ($Million)
  • Table 04. Biologics Psoriatic Arthritis Treatment Market, By Region, 2018-2026 ($Million)
  • Table 05. Others Psoriatic Arthritis Treatment Market, By Region, 2018-2026 ($Million)
  • Table 06. Global Psoriatic Arthritis Treatment Market, By Type, 2018-2026 ($Million)
  • Table 07. Prescription Psoriatic Arthritis Treatment Market, By Region, 2018-2026 ($Million)
  • Table 08. Otc Psoriatic Arthritis Treatment Market, By Region, 2018-2026 ($Million)
  • Table 09. Global Psoriatic Arthritis Treatment Market, By Route of Administration, 2018-2026 ($Million)
  • Table 10. Injectable Psoriatic Arthritis Treatment Market, By Region, 2018-2026 ($Million)
  • Table 11. Oral Psoriatic Arthritis Treatment Market, By Region, 2018-2026 ($Million)
  • Table 12. Topical Psoriatic Arthritis Treatment Market, By Region, 2018-2026 ($Million)
  • Table 13. Psoriatic Arthritis Treatment Market, By Region, 2018-2026 ($Million)
  • Table 14. North America Psoriatic Arthritis Treatment Market, By Country, 2018-2026 ($Million)
  • Table 15. U.S. Psoriatic Arthritis Treatment Market, By Drug Type, 2018-2026
  • Table 16. U.S. Psoriatic Arthritis Treatment Market, By Type, 2018-2026
  • Table 17. U.S. Psoriatic Arthritis Treatment Market, By Route of Administration, 2018-2026
  • Table 18. Canada Psoriatic Arthritis Treatment Market, By Drug Type, 2018-2026
  • Table 19. Canada Psoriatic Arthritis Treatment Market, By Type, 2018-2026
  • Table 20. Canada Psoriatic Arthritis Treatment Market, By Route of Administration, 2018-2026
  • Table 21. Mexico Psoriatic Arthritis Treatment Market, By Drug Type, 2018-2026
  • Table 22. Mexico Psoriatic Arthritis Treatment Market, By Type, 2018-2026
  • Table 23. Mexico Psoriatic Arthritis Treatment Market, By Route of Administration, 2018-2026
  • Table 24. North America Psoriatic Arthritis Treatment Market, By Drug Type, 2018-2026
  • Table 25. North America Psoriatic Arthritis Treatment Market, By Type, 2018-2026
  • Table 26. North America Psoriatic Arthritis Treatment Market, By Route of Administration, 2018-2026
  • Table 27. Europe Psoriatic Arthritis Treatment Market, By Country, 2018-2026 ($Million)
  • Table 28. Germany Psoriatic Arthritis Treatment Market, By Drug Type, 2018-2026
  • Table 29. Germany Psoriatic Arthritis Treatment Market, By Type, 2018-2026
  • Table 30. Germany Psoriatic Arthritis Treatment Market, By Route of Administration, 2018-2026
  • Table 31. France Psoriatic Arthritis Treatment Market, By Drug Type, 2018-2026
  • Table 32. France Psoriatic Arthritis Treatment Market, By Type, 2018-2026
  • Table 33. France Psoriatic Arthritis Treatment Market, By Route of Administration, 2018-2026
  • Table 34. Uk Psoriatic Arthritis Treatment Market, By Drug Type, 2018-2026
  • Table 35. Uk Psoriatic Arthritis Treatment Market, By Type, 2018-2026
  • Table 36. Uk Psoriatic Arthritis Treatment Market, By Route of Administration, 2018-2026
  • Table 37. Italy Psoriatic Arthritis Treatment Market, By Drug Type, 2018-2026
  • Table 38. Italy Psoriatic Arthritis Treatment Market, By Type, 2018-2026
  • Table 39. Italy Psoriatic Arthritis Treatment Market, By Route of Administration, 2018-2026
  • Table 40. Spain Psoriatic Arthritis Treatment Market, By Drug Type, 2018-2026
  • Table 41. Spain Psoriatic Arthritis Treatment Market, By Type, 2018-2026
  • Table 42. Spain Psoriatic Arthritis Treatment Market, By Route of Administration, 2018-2026
  • Table 43. Rest of Europe Psoriatic Arthritis Treatment Market, By Drug Type, 2018-2026
  • Table 44. Rest of Europe Psoriatic Arthritis Treatment Market, By Type, 2018-2026
  • Table 45. Rest of Europe Psoriatic Arthritis Treatment Market, By Route of Administration, 2018-2026
  • Table 46. Europe Psoriatic Arthritis Treatment Market, By Drug Type, 2018-2026
  • Table 47. Europe Psoriatic Arthritis Treatment Market, By Type, 2018-2026
  • Table 48. Europe Psoriatic Arthritis Treatment Market, By Route of Administration, 2018-2026
  • Table 49. Asia-Pacific Psoriatic Arthritis Treatment Market, By Country, 2018-2026 ($Million)
  • Table 50. Japan Psoriatic Arthritis Treatment Market, By Drug Type, 2018-2026
  • Table 51. Japan Psoriatic Arthritis Treatment Market, By Type, 2018-2026
  • Table 52. Japan Psoriatic Arthritis Treatment Market, By Route of Administration, 2018-2026
  • Table 53. China Psoriatic Arthritis Treatment Market, By Drug Type, 2018-2026
  • Table 54. China Psoriatic Arthritis Treatment Market, By Type, 2018-2026
  • Table 55. China Psoriatic Arthritis Treatment Market, By Route of Administration, 2018-2026
  • Table 56. Australia Psoriatic Arthritis Treatment Market, By Drug Type, 2018-2026
  • Table 57. Australia Psoriatic Arthritis Treatment Market, By Type, 2018-2026
  • Table 58. Australia Psoriatic Arthritis Treatment Market, By Route of Administration, 2018-2026
  • Table 59. India Psoriatic Arthritis Treatment Market, By Drug Type, 2018-2026
  • Table 60. India Psoriatic Arthritis Treatment Market, By Type, 2018-2026
  • Table 61. India Psoriatic Arthritis Treatment Market, By Route of Administration, 2018-2026
  • Table 62. South Korea Psoriatic Arthritis Treatment Market, By Drug Type, 2018-2026
  • Table 63. South Korea Psoriatic Arthritis Treatment Market, By Type, 2018-2026
  • Table 64. South Korea Psoriatic Arthritis Treatment Market, By Route of Administration, 2018-2026
  • Table 65. Rest of Asia-Pacific Psoriatic Arthritis Treatment Market, By Drug Type, 2018-2026
  • Table 66. Rest of Asia-Pacific Psoriatic Arthritis Treatment Market, By Type, 2018-2026
  • Table 67. Rest of Asia-Pacific Psoriatic Arthritis Treatment Market, By Route of Administration, 2018-2026
  • Table 68. Asia-Pacific Psoriatic Arthritis Treatment Market, By Drug Type, 2018-2026
  • Table 69. Asia-Pacific Psoriatic Arthritis Treatment Market, By Type, 2018-2026
  • Table 70. Asia-Pacific Psoriatic Arthritis Treatment Market, By Route of Administration, 2018-2026
  • Table 71. Lamea Psoriatic Arthritis Treatment Market, By Country, 2018-2026 ($Million)
  • Table 72. Brazil Psoriatic Arthritis Treatment Market, By Drug Type, 2018-2026
  • Table 73. Brazil Psoriatic Arthritis Treatment Market, By Type, 2018-2026
  • Table 74. Brazil Psoriatic Arthritis Treatment Market, By Route of Administration, 2018-2026
  • Table 75. Saudi Arabia Psoriatic Arthritis Treatment Market, By Drug Type, 2018-2026
  • Table 76. Saudi Arabia Psoriatic Arthritis Treatment Market, By Type, 2018-2026
  • Table 77. Saudi Arabia Psoriatic Arthritis Treatment Market, By Route of Administration, 2018-2026
  • Table 78. South Africa Psoriatic Arthritis Treatment Market, By Drug Type, 2018-2026
  • Table 79. South Africa Psoriatic Arthritis Treatment Market, By Type, 2018-2026
  • Table 80. South Africa Psoriatic Arthritis Treatment Market, By Route of Administration, 2018-2026
  • Table 81. Rest of Lamea Psoriatic Arthritis Treatment Market, By Drug Type, 2018-2026
  • Table 82. Rest of Lamea Psoriatic Arthritis Treatment Market, By Type, 2018-2026
  • Table 83. Rest of Lamea Psoriatic Arthritis Treatment Market, By Route of Administration, 2018-2026
  • Table 84. Lamea Psoriatic Arthritis Treatment Market, By Drug Type, 2018-2026
  • Table 85. Lamea Psoriatic Arthritis Treatment Market, By Type, 2018-2026
  • Table 86. Lamea Psoriatic Arthritis Treatment Market, By Route of Administration, 2018-2026
  • Table 87. Abbvie Inc: Company Snapshot
  • Table 88. Abbvie Inc: Operating Segments
  • Table 89. Abbvie Inc: Product Portfolio
  • Table 90. Amgen: Company Snapshot
  • Table 91. Amgen: Product Segment
  • Table 92. Amgen: Product Portfolio
  • Table 93. Bms.: Operating Segment
  • Table 94. Bms.: Product Portfolio
  • Table 95. Lilly: Company Snapshot
  • Table 96. Lilly: Operating Segments
  • Table 97. Lilly: Product Portfolio
  • Table 98. J&J: Company Snapshot
  • Table 99. J&J: Operating Segments
  • Table 100. J&J: Product Portfolio
  • Table 101. Merck & Co., Inc: Company Snapshot
  • Table 102. Merck & Co., Inc: Operating Segments
  • Table 103. Merck & Co., Inc: Product Portfolio
  • Table 104. Mylan: Company Snapshot
  • Table 105. Mylan: Operating Segments
  • Table 106. Mylan: Product Portfolio
  • Table 107. Novartis Ag: Company Snapshot
  • Table 108. Novartis Ag: Operating Segments
  • Table 109. Novartis Ag: Product Portfolio
  • Table 110. Pfizer Inc: Company Snapshot
  • Table 111. Pfizer Inc: Operating Segments
  • Table 112. Pfizer Inc: Product Portfolio
  • Table 113. Ucb S.A.: Company Snapshot
  • Table 114. Ucb S.A.: Product Portfolio

List of Figures

  • Figure 01. Global Psoriatic Arthritis Treatment Market Segmentation
  • Figure 02. Top Investment Pockets
  • Figure 03. High Bargaining Power of Suppliers
  • Figure 04. Moderate Bargaining Power of Buyers
  • Figure 05. High Threat of Substitutes
  • Figure 06. Moderate Threat of New Entrants
  • Figure 07. High Intensity of Rivalry
  • Figure 08. Impact Analysis
  • Figure 09. Comparative Analysis of Nsaids Psoriatic Arthritis Treatment Market, By Country, 2018 & 2026 ($Million)
  • Figure 10. Comparative Analysis of Dmards Psoriatic Arthritis Treatment Market, By Country, 2018 & 2026 ($Million)
  • Figure 11. Comparative Analysis of Biologics Psoriatic Arthritis Treatment Market, By Country, 2018 & 2026 ($Million)
  • Figure 12. Comparative Analysis of Others Psoriatic Arthritis Treatment Market, By Country, 2018 & 2026 ($Million)
  • Figure 13. Comparative Analysis of Prescription Psoriatic Arthritis Treatment Market, By Country, 2018 & 2026 ($Million)
  • Figure 14. Comparative Analysis of Otc Psoriatic Arthritis Treatment Market, By Country, 2018 & 2026 ($Million)
  • Figure 15. Comparative Analysis of Injectable Psoriatic Arthritis Treatment Market, By Country, 2018 & 2026 ($Million)
  • Figure 16. Comparative Analysis of Oral Psoriatic Arthritis Treatment Market, By Country, 2018 & 2026 ($Million)
  • Figure 17. Comparative Analysis of Topical Psoriatic Arthritis Treatment Market, By Country, 2018 & 2026 ($Million)
  • Figure 18. Abbvie Inc: Net Sales, 2016-2018 ($Million)
  • Figure 19. Abbvie Inc: Revenue Share By Segment, 2018 (%)
  • Figure 20. Abbvie Inc: Revenue Share By Region, 2018(%)
  • Figure 21. Amgen: Net Sales, 2016-2018 ($Million)
  • Figure 22. Amgen: Revenue Share By Region, 2018(%)
  • Figure 23. Bms: Net Sales, 2016-2018 ($Million)
  • Figure 24. Bms: Revenue Share By Region, 2018(%)
  • Figure 25. Lilly: Net Sales, 2016-2018 ($Million)
  • Figure 26. Lilly: Revenue Share By Segment, 2018 (%)
  • Figure 27. Lilly: Revenue Share By Region, 2018(%)
  • Figure 28. J&J: Net Sales, 2016-2018 ($Million)
  • Figure 29. J&J: Revenue Share By Segment, 2018 (%)
  • Figure 30. J&J: Revenue Share By Geography, 2018 (%)
  • Figure 31. Merck & Co., Inc: Net Sales, 2016-2018 ($Million)
  • Figure 32. Merck & Co., Inc: Revenue Share By Segment, 2018 (%)
  • Figure 33. Merck & Co., Inc: Revenue Share By Geography, 2018 (%)
  • Figure 34. Mylan: Net Sales, 2016-2018 ($Million)
  • Figure 35. Mylan: Revenue Share By Geography, 2018 (%)
  • Figure 36. Novartis Ag: Net Sales, 2016-2018 ($Million)
  • Figure 37. Novartis Ag: Revenue Share By Segment, 2018 (%)
  • Figure 38. Novartis Ag: Revenue Share By Region, 2018(%)
  • Figure 39. Pfizer Inc: Net Sales, 2016-2018 ($Million)
  • Figure 40. Pfizer Inc: Revenue Share By Segment, 2018 (%)
  • Figure 41. Pfizer Inc: Revenue Share By Region, 2018(%)
  • Figure 42. Ucb S.A.: Net Sales, 2016-2018 ($Million)
  • Figure 43. Ucb S.A.: Revenue Share By Segment, 2018 (%)
  • Figure 44. Ucb S.A.: Revenue Share By Geography, 2018 (%)
Back to Top